Our guest author is David L. Wyles, MD, Associate Professor of Medicine, Division of Infectious Diseases at the University of California San Diego.

After participating in this activity, the participant will demonstrate the ability to:

• Evaluate the treatment options for patients with genotype 2 and genotype 3 HCV infection, including those with cirrhosis.
• Summarize the phase 3 clinical trial data investigating the new DAA regimen of grazoprevir plus elbasvir.
• Describe the limitations in currently available retreatment options for patients failing interferon-free DAA regimens, including the importance resistance may play in retreatment success.

This discussion, offered as a downloadable audio file and companion transcript, covers the important topic of new DAA regimens for the treatment of genotype 2 and genotype 3 HCV infection, as well as their potential use in retreatment in the format of case-study scenarios for the clinical practice. This program is a follow up to the Volume 4, Issue 1 eViralHepatitis Review newsletter—New HCV DAA Regimens, Retreatment, and Optimizing Treatment of Genotype 2/3 Infection.

Unlabeled/Unapproved Uses
Dr. Wyles has indicated that there will be references to the use of grazoprevir plus elbasvir for the treatment of HCV infection – this combination in not currently FDA approved for the treatment of HCV infection and is still considered investigational.

		MEET THE AUTHOR
				David L. Wyles, MD Associate Professor of Medicine Division of Infectious Diseases University of California San Diego San Diego, California

Guest Faculty Disclosure
Dr. Wyles has disclosed that he has received grant and/or research funding from AbbVie, Bristol-Myers Squibb, Gilead, and Merck, and has provided advisory consult for Janssen.

Mark S. Sulkowski, MD
Professor of Medicine
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Raymond T. Chung, MD
Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Johns Hopkins University School of Medicine
Harvard Medical School
Boston, Massachusetts

Julie McArthur, MS, CRNP
Adult Nurse Practitioner
Division of Infectious Disease
Johns Hopkins University School of Medicine
Baltimore, Maryland

ACCREDITATION STATEMENT

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Nurses
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

Physicians
Podcast: The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Podcast: This 0.5 contact hour Educational Activity is provided by the Institute for Johns Hopkins Nursing. Each Podcast carries a maximum of 0.5 contact hour, or a total of 3 contact hours for the 6 podcasts in this program.

All rights reserved - The Johns Hopkins University School of Medicine.

This activity was developed in collaboration with DKBmed.